Shots:
- Moderna reported the publication of the second interim analysis of the open-label P-I study of mRNA-1273 in the NEJM. The study evaluated a 2dose vaccination schedule of mRNA-1273 given 28 days apart in 40 adults across two dose levels (25/100µg) in two age cohorts (56-70/ 71+) and reports results @Day 57 (1mos. following the second dose)
- mRNA-1273 induced consistently high levels of pseudovirus neutralization Ab titers in all participants, elicited Th1-biased CD4 T cell responses across all age group, neutralizing Ab titers and T cell responses is consistent with reported in younger adults, both the doses were well tolerated
- Results were consistent using 3 live virus assays. Additionally, the US government has agreed to purchase 100M doses of mRNA-1273, with an option to purchase an additional 400M dose
Click here to read full press release/ article | Ref: Moderna | Image: Stat
The post Moderna’s mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults first appeared on PharmaShots.
